Previous 10 | Next 10 |
-- Gilead Adds Trodelvy TM , First-in-Class Antibody-Drug Conjugate Approved to Treat Triple-Negative Breast Cancer, With Promise in Other Forms of Breast Cancer and Additional Solid Tumors -- -- Acquisition Transforms Gilead’s Portfolio with First-in-Class Commercial Pro...
Gilead Sciences (NASDAQ: GILD ) is close to a deal to buy Immunomedics (NASDAQ: IMMU ) and its prized Trodelvy breast cancer drug for more than $20B, with an announcement expected by Monday or sooner, WSJ reports. More news on: Gilead Sciences, Inc., Immunomedics, Inc., Healthcare ...
Breadth of presentations include i) Full results from ASCENT; ii) Final results from TROPHY U-01 cohort 1; iii) First results with Trodelvy ™ in brain tumors Conference call and webcast with key opinion leaders on September 19, 2020 MORRIS PLAINS, N.J., Sept. ...
August 25, 2020 FN Media Group Presents USA News Group News Commentary Vancouver, BC – August 25, 2020 – USA News Group – In the fight against some of the most challenging forms of cancer, AstraZeneca PLC (NYSE:AZN) recently placed a giant $6 ...
Social distancing measures aimed at controlling the coronavirus pandemic have slowed down a lot of government agencies, but they haven't prevented regulators from reviewing new drug applications at a rapid pace. The FDA has already approved 35 novel new drugs this year, and keeping up with all o...
MORRIS PLAINS, N.J., Aug. 17, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates (ADC), today announced that the U.S. Food and Drug Admini...
Image source: The Motley Fool. Immunomedics Inc (NASDAQ: IMMU) Q2 2020 Earnings Call Aug 5, 2020 , 5:00 p.m. ET Operator Continue reading
Immunomedics, Inc. (IMMU) Q2 2020 Results Conference Call August 05, 2020 05:00 PM ET Company Participants Chau Cheng - Senior Director-Investor Relations Dr. Behzad Aghazadeh - Executive Chairman Brendan Delaney - Chief Commercial Officer Dr. Loretta Itri - Chief Medical Offic...
Immunomedics (NASDAQ: IMMU ) : Q2 GAAP EPS of -$0.30 beats by $0.04 . More news on: Immunomedics, Inc., Earnings news and commentary, Stocks on the move, Healthcare stocks news, Read more ...
Encouraging early adoption of Trodelvy ™ in U.S. with $20.1M net sales in first two months of launch Confirmatory Phase 3 ASCENT study met primary endpoint of progression-free survival and key secondary endpoints of overall survival and objective response rate Full ASCEN...
News, Short Squeeze, Breakout and More Instantly...
Gilead Sciences (NASDAQ: GILD) can be both a hero and a goat, depending on your perspective as an investor. The stock price rose from $17 in July 2010 to $118 in July 2015, as the company introduced revolutionary HIV drugs and helped bring a cure for hepatitis C to market. Since the...
With huge investments being made in biotech thanks to the pandemic, there has been a renewed focus on biotech stocks. Here are three worth considering: Amgen (AMGN), Immunomedics (IMMU), Seattle Genetics (SGEN), and Genmab (GMAB). The biotechnology industry has rightfully received a huge ...
MORRIS PLAINS, N.J., Oct. 12, 2020 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (NASDAQ: IMMU) (“Immunomedics” or the “Company”), a leading biopharmaceutical company in the area of antibody-drug conjugates, today announced that the Office of Orphan Products...